In contrast to the CRPC-adenocarcinoma patients, CRPC-NE patients showed reduced frequency of genomic alterations associated with androgen receptor (AR), indicating the selection of AR-independent clonal subpopulation during NEPC progression (Beltran et al., 2016). This evidence concerns the gene AR and adenocarcinoma.